Dermatology key references

Reference

Summary

Elmets et al, 2021

Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.

Reference

Summary

Menter et al, 2020

Guideline from the American Academy of Dermatology and National Psoriasis Foundation reviews efficacy and safety and provides recommendations for commonly used medications, including methotrexate, cyclosporine, and acitretin. Discussion also includes newer therapies, tofacitinib and apremilast, and other less commonly used systemic agents.

Reference

Summary

Warren et al, 2017

An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Prospective, multicentre, randomised, double-blind, placebo-controlled trial subcutaneous MTX vs placebo.

PASI75 response at 16 weeks was 41% in MTX group and 10% in placebo group (relative risk 3.93, 95%CI 1.31-11.81).

Reference

Summary

Menter et al, 2020

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

Guideline from the American Academy of Dermatology and National Psoriasis Foundation reviews evidence and provides recommendations for the use of biologic agents in the treatment of adult psoriasis.

Smith et al, 2020

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update.

British Association of Dermatologists guidelines, updated in 2020, with evidence-based recommendations on the use of biologic therapies in adults, children and young people for the treatment of psoriasis.

Reference

Summary

Jørgensen et al, 2017

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Non-inferiority, double-blind trial including 482 patients on stable treatment with infliximab originator. Patients were randomised in a 1:1 ratio to continue infliximab originator or switch to biosimilar infliximab treatment, with unchanged dosing regimen. Patients were being treated for a range of conditions – 55 (32%) had Crohn disease, 93 (19%) had ulcerative colitis, 91 (19%) had spondyloarthritis, 77 (16%) had rheumatoid arthritis, 30 (6%) had psoriatic arthritis, and 35 (7%) had chronic plaque psoriasis.

Over 52 weeks, disease worsening occurred in 53 (26%) patients in the infliximab originator group and 61 (30%) patients in the biosimilar infliximab group.

The frequency of adverse events was similar between groups (for serious adverse events, 24 (10%) for infliximab originator vs 21(9%) for biosimilar infliximab; for overall adverse events, 168 (70%) vs 164 (68%); and for adverse events leading to discontinuation, 9 (4%) vs 8 (3%), respectively.